Onspira’s team of dedicated leaders brings together decades of experience developing, achieving approval and commercializing medicines to solve challenging clinical problems in order to improve patients' lives.
President and Chief Executive Officer
Brian Lortie is a co-founder of Onspira Therapeutics and has served as President and Chief Executive Officer and as a member of the Board of Directors since its inception in 2017. During a career spanning more than 25 years of pharmaceutical leadership, Brian has built and led successful teams ranging from small, entrepreneurial startup ventures to large country operations and business units. He is a results-oriented leader with a record of achievement across all key areas including commercialization, clinical development, regulatory affairs, medical affairs, supply chain and business development. Prior to joining Onspira Therapeutics, Brian was President, Branded Pharmaceuticals at Endo Pharmaceuticals. He joined Endo in 2009 after spending much of his career with GlaxoSmithKline (GSK) and its predecessor companies. At GSK, his career progressed from sales to marketing in the US, then to Europe as Managing Director – Ireland. Returning to the US, Brian was Vice President and Business Unit Head for Diabetes, Urology and Anti-Infective Products, a portfolio which approached $3 billion in revenue. Brian returned to Europe for a role with the GSK Biologicals organization in Belgium as Vice President and Global Head – HPV Vaccine Franchise, where he held global responsibility for the development, registration and commercialization of GSK’s vaccine against HPV and cervical cancer. Following this, he returned to the US in a senior business development role where he led several product and business M&A activities. Brian holds a BA with honors in Biology and Psychology from Boston University and studied at the Villanova University Graduate School of Business.
Roy Clifford Levitt, MD
Chief Scientific Officer
Roy Levitt, MD, has more than 35 years of experience as a physician-scientist and 22 years in pharmaceuticals development including leadership in development stage and global commercial biopharmaceuticals. Roy is co-founder of Onspira Therapeutics and serves as its Chief Scientific Officer and as a member of the Board of Directors. He is a board-certified anesthesiologist, internist and practicing pain specialist with over 125 peer-reviewed publications. He is also a serial inventor and entrepreneur with more than 20 issued patents. Prior to joining Onspira, he created and led multiple biopharmaceutical companies and held various positions of increasing responsibility including Medical Director, Commercial Operations, CSL Behring; and Chief Executive Officer, President and board member of Genera Corporation. Roy earned a BS in chemistry and an MD from the University of Maryland. He completed graduate and advanced training in anesthesiology, genetics and internal medicine at The Johns Hopkins Medical Institutions; and as an inter-institutes medical genetics fellow at the National Institutes of Health.
Chief Financial Officer
Doug Gessl has more than 12 years of experience in biotech and nearly 20 years in the financial services sector. He is also a partner in NeXeption. Additionally, he is the Chief Financial Officer for Velicept Therapeutics as well as Ralexar Therapeutics. Doug served as Chief Operating Officer and Chief Financial Officer of Ceptaris Therapeutics (acquired by Actelion) and Chief Financial Officer and Senior Vice President of Ception Therapeutics (acquired by Cephalon). Previously, Doug was a Senior Vice President with Einhorn Associates where he acted as financial advisor for mergers and acquisitions as well as lead advisor for the first institutional financing for Fulcrum Pharmaceuticals, Inc., a legacy company to Ception. His experience prior to entering the biopharmaceutical industry covers approximately 20 years, completing merger and acquisition transactions, public and private capital and structured finance offerings for clients. He also held roles in international strategic planning and consulting. Doug received his MBA from the University of Chicago and a BBA in Finance, Investments and Banking from the University of Wisconsin.
Vice President – Commercial Strategy
Kelly Copeland has more than 18 years of experience working in the healthcare industry. She is a partner with NeXeption and serves as the Vice President of Commercial Strategy for Onspira. Additionally, she is the Vice President of Commercial Strategy for Velicept Therapeutics as well as Ralexar Therapeutics. Previously, Kelly was Vice President of Commercial Strategy for Aclaris Therapeutics (NASDAQ: ACRS) as well as Vice President of Product Strategy and Marketing for Ceptaris Therapeutics (acquired by Actelion) and Vice President of Product Strategy and Business Development for Ception Therapeutics (acquired by Cephalon). She spent six years with GlaxoSmithKline providing commercial strategy and product development support. Prior to GlaxoSmithKline, Kelly held positions at Henry Ford Health System and Provider Partnerships, Inc. Kelly earned her MS in Health Services Administration and a BS from the University of Michigan. Additionally, she completed a post-graduate fellowship with Henry Ford Health System.
Head - Operations & Supply Chain
Rohit Mehta has nearly 25 years of broad and global experience in biopharmaceutical supply chain, operations, and business/corporate development. Most recently, Rohit was Senior Vice President of Corporate Development and Head of Supply Chain at Iroko Pharmaceuticals, and President of Iroko Pharmaceuticals (Puerto Rico), where he led all business/corporate development activities and successfully established a global supply chain comprising eight manufacturers and seven suppliers across four continents. In addition, Rohit led the Trade Relations function at Iroko. Prior to joining Iroko, Rohit served as Vice President, Corporate Development at Dr. Reddy’s Laboratories (US), Vice President of Corporate Development at EpiCept Corporation (now Immune Pharmaceuticals), and as Director, Business Development at Endo Pharmaceuticals. Mr. Mehta earned an MBA in International Business from Temple University, an MS in plastic engineering from the University of Massachusetts at Lowell, and a B.Sc. in chemistry from Bombay University.